Getting the Right Evidence After Drug Approval

Rick A Vreman; Hubert G M Leufkens; Aaron S Kesselheim

doi:10.3389/fphar.2020.569535

Getting the Right Evidence After Drug Approval

Rick A Vreman, Hubert G M Leufkens, Aaron S Kesselheim

Program on Regulation, Therapeutics and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital/Harvard Medical School, Boston, MA, United States.

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

To generate comparative evidence in a timely fashion for drugs without restricting or delaying access, value-based pricing and reimbursement could be conditioned on a prospective, post-approval evidence generation plan.

Original language	English
Article number	569535
Number of pages	3
Journal	Frontiers in Pharmacology
Volume	11
DOIs	https://doi.org/10.3389/fphar.2020.569535
Publication status	Published - 9 Sept 2020

Keywords

evidence
comparative evidence
regulation
pricing
value-based
health technology assessment
reimbursement

Access to Document

10.3389/fphar.2020.569535

fphar-11-569535Final published version, 216 KB

Cite this

@article{d8e0648f2c0f4333ac17cef3c7190cc3,

title = "Getting the Right Evidence After Drug Approval",

abstract = "To generate comparative evidence in a timely fashion for drugs without restricting or delaying access, value-based pricing and reimbursement could be conditioned on a prospective, post-approval evidence generation plan.",

keywords = "evidence, comparative evidence, regulation, pricing, value-based, health technology assessment, reimbursement",

author = "Vreman, {Rick A} and Leufkens, {Hubert G M} and Kesselheim, {Aaron S}",

note = "Copyright {\textcopyright} 2020 Vreman, Leufkens and Kesselheim.",

year = "2020",

month = sep,

day = "9",

doi = "10.3389/fphar.2020.569535",

language = "English",

volume = "11",

journal = "Frontiers in Pharmacology",

issn = "1663-9812",

publisher = "Frontiers Media SA",

}

TY - JOUR

T1 - Getting the Right Evidence After Drug Approval

AU - Vreman, Rick A

AU - Leufkens, Hubert G M

AU - Kesselheim, Aaron S

PY - 2020/9/9

Y1 - 2020/9/9

N2 - To generate comparative evidence in a timely fashion for drugs without restricting or delaying access, value-based pricing and reimbursement could be conditioned on a prospective, post-approval evidence generation plan.

AB - To generate comparative evidence in a timely fashion for drugs without restricting or delaying access, value-based pricing and reimbursement could be conditioned on a prospective, post-approval evidence generation plan.

KW - evidence

KW - comparative evidence

KW - regulation

KW - pricing

KW - value-based

KW - health technology assessment

KW - reimbursement

U2 - 10.3389/fphar.2020.569535

DO - 10.3389/fphar.2020.569535

M3 - Article

C2 - 33013409

SN - 1663-9812

VL - 11

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

M1 - 569535

ER -

Getting the Right Evidence After Drug Approval

Abstract

Keywords

Access to Document

Fingerprint

Cite this